Imakiire Toshihiko, Kikuchi Yuichi, Yamada Muneharu, Kushiyama Taketoshi, Higashi Keishi, Hyodo Naomi, Yamamoto Kojiro, Oda Takashi, Suzuki Shigenobu, Miura Soichiro
Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
Hypertens Res. 2007 Jul;30(7):635-42. doi: 10.1291/hypres.30.635.
The mechanisms of hypertensive nephrosclerosis are not fully understood. In experimental models of the disease, inflammatory reactions such as macrophage infiltration play an important role. In human hypertensive nephrosclerosis, however, there have been few studies examining the role of inflammation histologically. We investigated whether the number of infiltrating macrophages was increased in human hypertensive nephrosclerosis, and evaluated the effects of a blockade of the renin-angiotensin system on clinical and histological findings. We examined macrophage infiltration using immunohistochemistry in renal biopsy specimens obtained from 16 patients with hypertensive nephrosclerosis, 5 patients with IgA nephropathy, 5 patients with membranous nephropathy, and 5 patients with minimal change nephrotic syndrome. The number of infiltrating macrophages in glomeruli was significantly larger in the patients with hypertensive nephrosclerosis than in those with minimal change nephrotic syndrome. The patients with hypertensive nephrosclerosis were divided into groups based on their use of antihypertensive agents at the time of renal biopsy. We investigated the effects of antihypertensive agents on clinical findings, macrophage infiltration, and monocyte chemoattractant protein-1 expression. There was no difference in clinical findings between the hypertensive groups. The numbers of infiltrating macrophages and monocyte chemoattractant protein-1-positive cells in glomeruli were significantly smaller in patients treated with an angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker, whereas calcium channel blockers had no influence on histological findings. In conclusion, inflammation is involved in the progression of human hypertensive nephrosclerosis and the inflammatory process is inhibited by blocking the renin-angiotensin system.
高血压性肾硬化的发病机制尚未完全明确。在该疾病的实验模型中,诸如巨噬细胞浸润等炎症反应发挥着重要作用。然而,在人类高血压性肾硬化中,从组织学角度研究炎症作用的相关研究较少。我们研究了人类高血压性肾硬化中浸润巨噬细胞的数量是否增加,并评估了肾素 - 血管紧张素系统阻断对临床和组织学结果的影响。我们采用免疫组织化学方法检查了从16例高血压性肾硬化患者、5例IgA肾病患者、5例膜性肾病患者和5例微小病变肾病综合征患者获取的肾活检标本中的巨噬细胞浸润情况。高血压性肾硬化患者肾小球中浸润巨噬细胞的数量显著多于微小病变肾病综合征患者。根据高血压性肾硬化患者肾活检时使用的降压药物,将他们分为不同组。我们研究了降压药物对临床结果、巨噬细胞浸润和单核细胞趋化蛋白 -1表达的影响。高血压组之间的临床结果没有差异。使用血管紧张素转换酶抑制剂或1型血管紧张素II受体阻滞剂治疗的患者,肾小球中浸润巨噬细胞和单核细胞趋化蛋白 -1阳性细胞的数量显著减少,而钙通道阻滞剂对组织学结果没有影响。总之,炎症参与了人类高血压性肾硬化的进展,并且通过阻断肾素 - 血管紧张素系统可抑制炎症过程。